MedTrace Logo

Milrinone Inhaled in Cardiac Surgery

NCT00819377 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2013-10-25

No results posted yet for this study

Summary

Pulmonary hypertension is an important morbidity factor in patients having to undergo cardiac surgery with cardiopulmonary bypass (ECC). Milrinone used in inhalation, shows evidence of being a pulmonary vasodilator able to possibly contribute to the reduction of pressure on the pulmonary artery.

Conditions

Interventions

DRUG

Milrinone

inhaled milrinone 5 mg (as for the injectable solution)

DRUG

Normal saline

5 ml normal saline by inhalation over 15 min

Sponsors & Collaborators

  • Heart and stoke fondation of Quebec

    collaborator UNKNOWN

  • Organon

    collaborator INDUSTRY

  • Canadian Anesthesiologists' Society

    collaborator OTHER

  • Andre Denault

    lead OTHER

Principal Investigators

  • Denault André, MD FRCPC · Montreal Heart Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-01-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819377 on ClinicalTrials.gov